secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001140361-23-051009
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire successful End-of-Phase 2 meeting with FDA for oral APX3330 in diabetic retinopathy
--------------------------------------------------------------------------------

- FDA agreed on Phase 3 primary endpoint: ≥3-step worsening on binocular DRSS; SPA to be submitted.
- APX3330 could be first oral option for ~8M US NPDR patients; Phase 2 ZETA-1 showed slowing of DR progression.
- Company plans Special Protocol Assessment to finalize trial design and timing with FDA.
- Phase 2 ZETA-1 met primary endpoint: lower % of APX3330-treated patients had ≥3-step worsening vs placebo at 24 weeks.
- APX3330 demonstrated favorable safety/tolerability; CEO calls it 'most advanced oral therapy in development for DR'.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123051009/0001140361-23-051009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123051009/ef20013910_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-051009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer